In this article, Gregory Vistnes outlines why Antitrust Agencies care about clinical integration, an issue that might seem primarily an issue of concern to the healthcare community and not antitrust enforcers, and how the agencies typically evaluate the competitive significance of clinical integration.
How compulsory licensing shaped innovation in the Xerox case
In a new article published in the Journal of Industrial Economics, CRA’s Robin Mamrak shows that opening up an incumbent’s patent portfolio can promote...